 Home > Medical News > Latest Medical News > Chengdu Xiandao HG146 Capsule New Indication Clinical Trial Application Approved

Chengdu Xiandao HG146 Capsule New Indication Clinical Trial Application Approved

 Last Update: 2021-05-22
 Source: Internet
 Author: User

Tags

motrin drug

ketotifen capsules

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Chengdu Pilot issued an announcement stating that the company has received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, and the company's research project "HG146 Capsules" (hereinafter referred to as "HG146") has been applied for clinical trials for expanding indications.

It is reported that this submission of HG146 capsules is a new class of chemical drug registration, and it is planned to add new indications for the treatment of patients with advanced solid tumors or lymphomas.

HG146 (HDAC I/IIb Subtype Selective Small Molecule Inhibitor) is a novel, selective type I and IIb histone deacetylase (HDAC) inhibitor with independent intellectual property rights developed by Chengdu.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.